Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phospholipase A2 Isoforms in Lung Immunity and Respiratory Infections: Potential Targets for Next-Generation Therapy.

International journal of molecular sciences·2026
Same author

Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities.

Frontiers in immunology·2026
Same author

Comparison of Routine PAP, Modified Ultrafast PAP (MUFP), and REAP Staining Techniques for Oral Cytosmears.

Journal of pharmacy & bioallied sciences·2026
Same author

Effectiveness of Token Economy Therapy in Reducing Aggressive Behaviors Among Orphanage Children: A Pilot Study.

Journal of pharmacy & bioallied sciences·2025
Same author

Compositional and functional characterization of cucumber and watermelon seed powders and their application in fortified dairy-based dessert.

Food chemistry: X·2025
Same author

Pediatric renal calyceal diverticular calculi: Diagnostic and management by percutaneous nephrolithotomy "case report".

Urology case reports·2025

Related Experiment Video

Updated: Jun 12, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

New insights into SYK targeting in solid tumors.

Shweta Joshi1

  • 1Division of Pediatric Hematology-Oncology, Moores Cancer Center, University of California, San Diego, CA 92093-0815, USA.

Trends in Pharmacological Sciences
|September 25, 2024
PubMed
Summary

Spleen tyrosine kinase (SYK) plays a dual role in solid tumors, sometimes suppressing and sometimes promoting cancer. Targeting SYK in immune cells within the tumor microenvironment offers new therapeutic strategies.

Keywords:
B cellsSYKmacrophagesmyeloid cellssolid tumorstumor microenvironment

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

Related Experiment Videos

Last Updated: Jun 12, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Spleen tyrosine kinase (SYK) is primarily found in hematopoietic cells, with established roles in B cell malignancies and autoimmune disorders.
  • SYK exhibits a paradoxical function in epithelial solid tumors, acting as a tumor suppressor in certain cancers and a promoter of tumor growth in others.
  • Emerging research highlights SYK's involvement in the tumor microenvironment (TME), where its signaling in immune cells contributes to immunosuppression and tumor progression.

Purpose of the Study:

  • To review the evolving roles of spleen tyrosine kinase (SYK) in the context of solid tumors.
  • To elucidate the mechanisms underlying SYK activation in cancer.
  • To summarize preclinical and clinical findings on SYK inhibitors for solid tumor treatment.

Main Methods:

  • Literature review of preclinical studies on SYK in solid tumors.
  • Analysis of research on SYK signaling pathways in immune cells (B cells, myeloid cells) within the TME.
  • Examination of clinical trial data for SYK inhibitors in monotherapy and combination treatments.

Main Results:

  • SYK signaling in immune cells within the TME promotes immunosuppression, tumor growth, and metastasis in various solid tumors.
  • SYK inhibitors are being investigated as potential standalone therapies or in combination with immunotherapy and chemotherapy.
  • The paradoxical role of SYK (tumor suppressor vs. promoter) is dependent on the specific cancer type and context.

Conclusions:

  • Targeting SYK in immune cells represents a promising therapeutic avenue for solid tumors.
  • Further research is needed to fully understand SYK's complex role and optimize inhibitor-based treatment strategies.
  • Combination therapies involving SYK inhibitors may enhance treatment efficacy in solid tumors.